Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06159608

Sex Differences in the Vascular Effects of E-cigarette Use

Status
Recruiting
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
Anna Stanhewicz, PhD · Academic / Other
Sex
All
Age
18 Years – 24 Years
Healthy volunteers
Accepted

Summary

The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored. In this study, we use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) we examine the blood vessels in a dime-sized area of the skin in otherwise healthy young (18-24yrs) chronic e-cigarette users. Local heating of the skin at the microdialysis sites is used to explore differences in mechanisms governing microvascular control. As a compliment to these measurements, we also draw blood from the subjects to measure circulating factors that may contribute to cardiovascular health and examine markers of inflammatory activation. We will also collect urine from female participants to measure estradiol.

Conditions

Interventions

TypeNameDescription
DRUGLocal heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)Differences in endothelium- and nitric oxide (NO)-dependent dilation between groups
OTHERChronic estrogen exposuredifferences in urine estrogen levels across the menstrual cycle between women groups only

Timeline

Start date
2023-12-02
Primary completion
2026-12-01
Completion
2026-12-01
First posted
2023-12-07
Last updated
2025-12-15

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT06159608. Inclusion in this directory is not an endorsement.